Early diagnosis of Parkinson's disease (PD) is required to improve therapeutic responses. Indeed, a clinical diagnosis of resting tremor, rigidity, movement and postural deficiencies usually reflect > 50% loss of the nigrostriatal system in disease. In a step to address this, quantitative diffusion tensor magnetic resonance imaging (DTI) was used to assess nigrostriatal degeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication model of dopaminergic nigral degeneration. We now demonstrate increased average diffusion (p < 0.005) and decreased fractional anisotropy (p < 0.03) in the substantia nigra (SN) of 5-to 7-day MPTP-treated animals when compared to saline controls. Transverse diffusivity demonstrated the most significant differences (p ≤ 0.002) and correlated with the numbers of SN dopaminergic neurons (r = −0.75, p = 0.012). No differences were found in the striatum, corpus callosum, cerebral cortex, or ventricles. These results demonstrate that DTI may be used as a surrogate biomarker of nigral dopaminergic neuronal degeneration.
Introduction
Parkinson's disease (PD) is a common and debilitating neurodegenerative disorder. Symptoms of tremor, rigidity, bradykinesia, and postural instability commonly progress to significant movement and cognitive dysfunction. Pathological changes in the substantia nigra pars compacta (SNpc) and striatum consist of nigral dopaminergic neuronal loss, intraneuronal cytoplasmic inclusions or "Lewy bodies", micro-and astro-gliosis, and striatal dopamine depletion (Fahn and Przedborski, 2000) . Innate immunity involving resident microglial cells with secretion of neurotoxic cytokines and production of reactive oxygen and nitrogen species contribute, in part, to nigrostriatal dopaminergic degeneration (Gao et al., 2003) . Disease is often advanced when classic clinical features manifest. Indeed, a diagnosis of PD is most commonly made in the later stages of disease when > 50% of SNpc neurons and their terminals are destroyed (Bernheimer et al., 1973) . If an early diagnosis could be made, it would enable interventional therapies at times when disease outcomes could yield positive results (Simpkins and Jankovic, 2003) .
In this regard, imaging research activities for PD have focused on finding better means to assess nigrostriatal degeneration. Functional imaging including single photon emission computerized tomography (Benamer et al., 2000) , positron emission tomography (Eidelberg et al., 1995; Morrish et al., 1996) , proton magnetic resonance spectroscopic imaging ( 1 H MRSI) (Cruz et al., 1997; Boska et al., 2005) , and functional magnetic resonance imaging (Ceballos-Baumann, 2003) have all proved promising but not definitive. One promising and new approach that has gained attention for tracking age-related changes in human brain and for the diagnosis of neurodegenerative diseases is magnetic resonance diffusion tensor imaging (DTI) (McGraw et al., 2005) . DTI tests have also been used in animal models of human disease such as multiple sclerosis and Alzheimer's disease (Song et al., 2004; Song et al., 2005) .
With this in mind, we developed and tested the ability of high field (7 T) mouse brain DTI to monitor dopaminergic neurodegeneration in the substantia nigra (SN) in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated mice (Vila and
